Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 10;608(7923):609–617. doi: 10.1038/s41586-022-05066-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Authors 2022, corrected publication 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 10 — a, 3,044 samples classified as either FGFR2-E18-truncated (n = 1,344, 44.2% of total, 0.54% incidence), amplified (n = 757, 24.8% of total, 0.30% incidence), or missense hotspot mutant (n = 943, 31.0% of total, 0.38% incidence) and top-30 co-enriched tumour driver alterations found in the FMI pan-cancer cohort (n = 249,570). b, Enrichments of top-30 tumour driver co-alterations in the indicated FGFR2 alteration categories in the FMI pan-cancer cohort. c, Odds ratios (OR) of top-30 tumour driver co-alterations in the indicated FGFR2 alteration categories (E18-truncation, n = 1,344; E1-E18 amp, n = 757; missense hotspot mut, n = 943) versus FGFR2 WT samples (n = 224,711) of the FMI pan-cancer cohort. Data are represented as log₂-transformed OR ± 95% confidence interval (CI). Co-occurrence, OR > 1; mutual exclusivity, OR < 1. d, Frequencies (top panel) and distributions (bottom panel) per tumour type of the indicated FGFR2 alteration categories in the FMI pan-cancer cohort. e, Enrichment of top tumour driver co-alterations in the indicated FGFR2 alteration categories in the FMI-CHOL, OV, COAD/READ, ESCA/STAD, and LUAD/LUSC cohorts. P values were calculated with one-tailed proportion z-tests (b, e) or two-tailed Fisher’s exact tests (c) and FDR multiple-testing corrections using the Benjamini-Hochberg method (b, c, e). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Sample sizes and statistical details for b, c, e are in Supplementary Table 2.

Source data